Merck & Co. Inc. continues to evaluate the information provided with an Abbreviated New Drug Application notice to determine what action should be taken.
In January 2009, the Company received notice…
The U.S. Patent and Trademark Office’s reexamination proceedings regarding Merck & Co. Inc.’s Singulair patent are ongoing.
In May 2009, the PTO granted a petition by Article One Partners LLC to…
Merck & Co. Inc.’s patent infringement lawsuits against generic pharmaceutical manufacturers who filed abbreviated new drug applications for its products.
Generic pharmaceutical manufacturers have submitted ANDA’s to the Food and Drug…
Medtronic Inc. and its subsidiary, Medtronic AVE, Inc. remain in dispute with Wyeth and Cordis Corporation over the alleged infringement of “Morris” patents.
On Feb. 22, 2008, Wyeth and Cordis Corporation…
Shire Ltd. is pursuing two suits against Nostrum Pharmaceuticals Inc. in the U.S. District Court for the District of New Jersey for the alleged infringement of U.S. Patent Nos. 5,912,013…
No trial date has been set for the litigation between Shire Ltd. and Apotex Inc., Apotex Corp. and Apotex Pharmaceutical Holdings Inc. for the alleged infringement of U.S. Patent Nos.…
A ruling on Merck & Co Inc.’s suit against Teva Pharmaceuticals Inc. in the U.S. District Court for the District of New Jersey for the alleged infringement of U.S. Patent…
Merck & Co. Inc. is evaluating the information provided with an Abbreviated New Drug Application (ANDA) notice to determine what action should be taken.
In January 2009, the Company received notice…
Merck & Co. Inc. and Schering-Plough Corporation continue to pursue litigation against generic companies over the infringement of the Zetia patent.
An abbreviated new drug application has been submitted to the…
Merck & Co. Inc. is considering its options regarding the Company’s European patent covering once-weekly dosing of Fosamax.
In September 2004, the Company appealed a decision of the Opposition Division of…